Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Branford

Showing results (361-370 of 480) with videos related to

Pageof 48
Sort By:
Nature Materials|November 13, 2023
Task-adaptive physical reservoir computingOscar Lee, Tianyi Wei, Kilian D Stenning, et al.
Angewandte Chemie (International Ed. in English)|September 23, 2016
Synthesis of a Ferrolite: A Zeolitic All-Iron FrameworkAllison M Latshaw, W Michael Chance, Gregory Morrison, et al.
Leukemia|October 28, 2015
Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion geneD M Ross, H K Altamura, C N Hahn, et al.
Journal of Physics. Condensed Matter : an Institute of Physics Journal|March 17, 2011
Experimental determination of the Rashba coefficient in InSb/InAlSb quantum wells at zero magnetic field and elevated temperaturesM A Leontiadou, K L Litvinenko, A M Gilbertson, et al.
BMC Cancer|April 4, 2013
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemiaAndrew M Stein, Giovanni Martinelli, Timothy P Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinibSusan Branford, Dong-Wook Kim, Simona Soverini, et al.
Blood|January 17, 2016
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinibWendy T Parker, David T O Yeung, Alexandra L Yeoman, et al.
Haematologica|July 7, 2018
<i>BCR-ABL1</i> genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemiaIlaria S Pagani, Phuong Dang, Ivar O Kommers, et al.
The Journal of Molecular Diagnostics : JMD|October 12, 2025
Enhanced Detection of Splice-Altering Variants in Hematologic Malignancies Using Targeted RNA-Sequencing DataMuneeza Maqsood, John Toubia, Carol Wadham, et al.
Plos One|September 23, 2014
Quantification of the heterogeneity of prognostic cellular biomarkers in ewing sarcoma using automated image and random survival forest analysisClaudia Bühnemann, Simon Li, Haiyue Yu, et al.
Pageof 48

Showing results (361-370 of 480) with videos related to

Sort By:
Pageof 48
Nature Materials|November 13, 2023
Task-adaptive physical reservoir computingOscar Lee, Tianyi Wei, Kilian D Stenning, et al.
Angewandte Chemie (International Ed. in English)|September 23, 2016
Synthesis of a Ferrolite: A Zeolitic All-Iron FrameworkAllison M Latshaw, W Michael Chance, Gregory Morrison, et al.
Leukemia|October 28, 2015
Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion geneD M Ross, H K Altamura, C N Hahn, et al.
Journal of Physics. Condensed Matter : an Institute of Physics Journal|March 17, 2011
Experimental determination of the Rashba coefficient in InSb/InAlSb quantum wells at zero magnetic field and elevated temperaturesM A Leontiadou, K L Litvinenko, A M Gilbertson, et al.
BMC Cancer|April 4, 2013
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemiaAndrew M Stein, Giovanni Martinelli, Timothy P Hughes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinibSusan Branford, Dong-Wook Kim, Simona Soverini, et al.
Blood|January 17, 2016
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinibWendy T Parker, David T O Yeung, Alexandra L Yeoman, et al.
Haematologica|July 7, 2018
<i>BCR-ABL1</i> genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemiaIlaria S Pagani, Phuong Dang, Ivar O Kommers, et al.
The Journal of Molecular Diagnostics : JMD|October 12, 2025
Enhanced Detection of Splice-Altering Variants in Hematologic Malignancies Using Targeted RNA-Sequencing DataMuneeza Maqsood, John Toubia, Carol Wadham, et al.
Plos One|September 23, 2014
Quantification of the heterogeneity of prognostic cellular biomarkers in ewing sarcoma using automated image and random survival forest analysisClaudia Bühnemann, Simon Li, Haiyue Yu, et al.
Pageof 48